Aug 22 (Reuters) - Eli Lilly And Co :
* Lilly and Astrazeneca receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
* Also announced planned initiation of a second phase 3 trial for azd3293 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.